Broadening Our Understanding Type 1 Diabetes Heterogeneity by Exploring Effects of Race/Ethnicity on Disease Trajectory

Martin J Hessner,Susanne M Cabrera
DOI: https://doi.org/10.1210/clinem/dgaa375
2020-06-15
Abstract:There is increasing recognition of heterogeneous pathogenic mechanisms underlying the immune mediated beta cell destruction that characterizes type 1 diabetes (T1D). Certainly, disease heterogeneity has long been clinically observed in the wide age range at diagnosis, variable insulin requirements, and differences in susceptibility to acute and chronic complications. Much of this may be attributed to the broad variability in residual beta-cell function at diagnosis and varying rates of functional beta-cell decline over time. Heterogeneity in beta-cell loss not only complicates clinical care but also confounds the use of beta-cell function, as measured by stimulated C-peptide during a standardized mixed meal tolerance test, as the primary (and clinically relevant) outcome measure in disease-modifying clinical trials that aim to preserve beta-cell function (<a class="link link-ref link-reveal xref-bibr" href="">1</a>).
What problem does this paper attempt to address?